Claims

1. Use of a BK channel antagonist or a composition comprising said antagonist for the manufacture of a medicament for the prophylaxis or treatment of seizures caused by one or more UBE3A mutations in a subject, wherein the one or more UBE3A mutations cause a BK channelopathy, wherein the BK channelopathy is characterized by an increase in BK channel activity, wherein the one or more UBE3A mutations result in loss or reduction of UBE3A function that causes said increased BK channel activity, and wherein the antagonist reduces said increased BK channel activity.
2. The use of claim 1, wherein the subject has Angelman syndrome or a related autism spectrum disorder caused by loss or reduction of function of the UBE3A gene.
3. The use of claim 1 or 2, wherein the compound is selected from the group comprising Paxilline, IBTX, and GAL-021.
4. The use of any one of claims 1 to 3, wherein the composition comprises pharmaceutically acceptable salts or solvates of said BK channel antagonist.
5. The use of any one of claims 1 to 4, wherein the composition comprises a pharmaceutically acceptable adjuvant, diluent or carrier.
6. The use of any one of claims 1 to 5, wherein the medicament is formulated for administration of a therapeutically effective amount of the BK channel antagonist in the range of 0.05 mg/kg to 10 mg/kg, 0.05 mg/kg to 5 mg/kg, preferably 0.3 mg/kg to 3 mg/kg body weight of the subject.
7. The use of any one of claims 1 to 6, wherein the antagonist is Paxilline.
8. The use of claim 7, wherein the Paxilline is to be administered at a therapeutically effective amount of 0.3 mg/kg to 3 mg/kg body weight of the subject.
9. The use of any one of claims 1 to 6, wherein the antagonist is IBTX.
10. The use of any one of claims 1 to 6, wherein the antagonist is Gal-021.